title: Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population.
abstract: BACKGROUND
  YKL-40 and C-reactive protein (CRP) are biomarkers that may reflect cancer-related subclinical inflammation. We assessed elevated YKL-40 and CRP levels as combined risk predictors for cancer.
  
  
  METHODS
  We measured plasma YKL-40 and CRP at baseline in 8706 individuals from the Danish general population.
  
  
  RESULTS
  Hazard ratio (HR) of gastrointestinal cancer for a doubling of YKL-40 levels was 1.37 (95% CI: 1.17-1.61) and indifferent to adjustment for CRP levels. Hazard ratio of lung cancer for a doubling of CRP levels was 1.35 (1.17-1.56) and indifferent to adjustment for YKL-40 levels. Compared to individuals with both low CRP (<1.7 mg l(-1)) and YKL-40 (<154 μg l(-1)), individuals with high YKL-40 but low CRP had an HR of gastrointestinal cancer of 3.36 (1.70-6.64), whereas individuals with high CRP but low YKL-40 had an HR of lung cancer of 2.19 (1.24-3.87). The area under the receiver operating characteristic (ROC) curve was 0.68 for the ability of YKL-40 to predict gastrointestinal cancer and 0.67 for the ability of CRP to predict lung cancer.
  
  
  CONCLUSIONS
  Elevated YKL-40 levels are associated with increased risk of gastrointestinal cancer, independently of CRP levels, whereas elevated CRP levels are associated with increased risk of lung cancer, independently of YKL-40 levels.
authors.affiliation: Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev 2730, Denmark.
authors.forename: K H
authors.initials: KH
authors.lastname: Allin
authors.forename: S E
authors.initials: SE
authors.lastname: Bojesen
authors.forename: J S
authors.initials: JS
authors.lastname: Johansen
authors.forename: B G
authors.initials: BG
authors.lastname: Nordestgaard
mesh_terms: D054392:Adipokines / Q000097:blood*; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D000071451:Chitinase-3-Like Protein 1; D003718:Denmark; D005260:Female; D006801:Humans; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D054392:Adipokines; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D037102:Lectins; D002097:C-Reactive Protein
references.citation: Clin Diagn Lab Immunol. 2002 May;9(3):598-604
references.pmid: 11986266
references.citation: J Clin Oncol. 2009 May 1;27(13):2217-24
references.pmid: 19289618
references.citation: Lung Cancer. 2004 Dec;46(3):333-40
references.pmid: 15541818
references.citation: Lung Cancer. 2005 May;48(2):223-31
references.pmid: 15829322
references.citation: Eur Heart J. 2002 Apr;23(8):620-6
references.pmid: 11969276
references.citation: Int J Epidemiol. 1988 Mar;17(1):44-9
references.pmid: 3384548
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5
references.pmid: 16614110
references.citation: Future Oncol. 2009 Sep;5(7):1065-82
references.pmid: 19792974
references.citation: Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15
references.pmid: 18402527
references.citation: Carcinogenesis. 2009 Jul;30(7):1073-81
references.pmid: 19468060
references.citation: Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):661-70
references.pmid: 17170368
references.citation: Br J Cancer. 1999 Mar;79(9-10):1494-9
references.pmid: 10188896
references.citation: J Infect Dis. 1999 Nov;180(5):1722-6
references.pmid: 10515841
references.citation: Cancer Res. 2006 Feb 15;66(4):2483-7
references.pmid: 16489056
references.citation: J Clin Oncol. 2009 Feb 1;27(4):572-8
references.pmid: 19075264
references.citation: JAMA. 2007 Jul 18;298(3):299-308
references.pmid: 17635890
references.citation: Eur Heart J. 2010 Jul;31(13):1624-32
references.pmid: 20423919
references.citation: J Natl Cancer Inst. 2010 Feb 3;102(3):202-6
references.pmid: 20056955
references.citation: Dan Med Bull. 1997 Nov;44(5):535-9
references.pmid: 9408738
references.citation: Clin Chem. 1998 Mar;44(3):509-16
references.pmid: 9510855
references.citation: J Am Coll Cardiol. 2010 Aug 31;56(10):789-95
references.pmid: 20797493
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):381-4
references.pmid: 16492932
references.citation: Lancet. 2001 Feb 17;357(9255):539-45
references.pmid: 11229684
references.citation: J Clin Invest. 2003 Jun;111(12):1805-12
references.pmid: 12813013
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8
references.pmid: 16214925
references.citation: Nature. 2002 Dec 19-26;420(6917):860-7
references.pmid: 12490959
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2719-26
references.pmid: 20421535
references.citation: IARC Sci Publ. 1991;(95):220-36
references.pmid: 1894325
references.citation: Ann Rheum Dis. 2000 Jul;59(7):544-8
references.pmid: 10873965
references.citation: Biochem J. 2002 Jul 1;365(Pt 1):119-26
references.pmid: 12071845
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5216-22
references.pmid: 17114654
references.citation: Curr Opin Lipidol. 2009 Oct;20(5):393-401
references.pmid: 19667982
references.citation: Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1672-8
references.pmid: 20466978
references.citation: JAMA. 2004 Feb 4;291(5):585-90
references.pmid: 14762037
references.citation: Cytokine. 2011 Jul;55(1):152-5
references.pmid: 21478032